Market Research Logo

Anal Cancer - Pipeline Review, H2 2016

Anal Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Anal Cancer - Pipeline Review, H2 2016’, provides an overview of the Anal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Anal Cancer
    • The report reviews pipeline therapeutics for Anal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Anal Cancer therapeutics and enlists all their major and minor projects
    • The report assesses Anal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Anal Cancer
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Anal Cancer
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Anal Cancer pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Anal Cancer Overview
    Therapeutics Development
    Pipeline Products for Anal Cancer - Overview
    Pipeline Products for Anal Cancer - Comparative Analysis
    Anal Cancer - Therapeutics under Development by Companies
    Anal Cancer - Therapeutics under Investigation by Universities/Institutes
    Anal Cancer - Pipeline Products Glance
    Clinical Stage Products
    Early Stage Products
    Anal Cancer - Products under Development by Companies
    Anal Cancer - Products under Investigation by Universities/Institutes
    Anal Cancer - Companies Involved in Therapeutics Development
    Advaxis, Inc.
    Amgen Inc.
    Cell Medica Limited
    Eli Lilly and Company
    Genticel S.A.
    ISA Pharmaceuticals B.V.
    Novartis AG
    Ono Pharmaceutical Co., Ltd.
    Oryx GmbH & Co. KG
    PDS Biotechnology Corporation
    Sun Pharma Advanced Research Company Ltd.
    Taiwan Liposome Company, Ltd.
    Anal Cancer - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    axalimogene filolisbac - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy for HPV Associated Cancers - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CMD-004 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GTL-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ISA-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nivolumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    paclitaxel albumin free - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    panitumumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PDR-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PDS-0101A - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    prexasertib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TLC-388 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vicoryx - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Anal Cancer - Dormant Projects
    Anal Cancer - Product Development Milestones
    Featured News & Press Releases
    Jun 08, 2016: Advaxis Announces First Patient Dosed in Phase 2 Trial Evaluating AXAL in Anal Cancer
    Jun 05, 2016: Nivolumab shows promise in first-ever trial for patients with refractory, metastatic anal cancer
    Dec 16, 2015: FDA Lifts Advaxis Clinical Hold On Axalimogene Filolisbac
    Dec 14, 2015: Advaxis Receives Orphan Drug Designation in the European Union for Axalimogene Filolisbac for the Treatment of Anal Cancer
    Dec 07, 2015: ISA Pharmaceuticals’ ISA101 Studied in Phase II Combination Trial with Checkpoint Inhibitor Nivolumab
    Nov 02, 2015: Advaxis Provides Additional Information on Clinical Hold
    Apr 06, 2015: Advaxis and RTOG Foundation to Collaborate on Pivotal Phase 2/3 Clinical Trial of ADXS-HPV in Anal Cancer
    Oct 15, 2014: Advaxis Provides Clinical Update for Phase 1/2 Trial of ADXS-HPV Immunotherapy Product Candidate in Anal Cancer
    Feb 11, 2014: SynCo Bio Partners Expands Live Microbial Product Experience
    Sep 16, 2013: ISA Pharmaceuticals Initiates Phase I/II Clinical Trial of ISA101 in Patients with Anal Intraepithelial Neoplasia
    Jun 24, 2013: Advaxis Requests Orphan Drug Designation For Treatment Of HPV-Associated Anal Cancer with ADXS-HPV
    Apr 22, 2013: Advaxis Announces First Patient Dosed In Brown University Sponsored Phase I/II Anal Cancer Study Of ADXS-HPV
    Mar 03, 2013: Advaxis Provides Update On ADXS-HPV Cancer Immunotherapy
    Feb 19, 2013: Advaxis Announces Brown University Oncology Group To Conduct Phase I/II Trial Of ADXS-HPV In Anal Cancer
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Anal Cancer, H2 2016
    Number of Products under Development for Anal Cancer - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Anal Cancer - Pipeline by Advaxis, Inc., H2 2016
    Anal Cancer - Pipeline by Amgen Inc., H2 2016
    Anal Cancer - Pipeline by Cell Medica Limited, H2 2016
    Anal Cancer - Pipeline by Eli Lilly and Company, H2 2016
    Anal Cancer - Pipeline by Genticel S.A., H2 2016
    Anal Cancer - Pipeline by ISA Pharmaceuticals B.V., H2 2016
    Anal Cancer - Pipeline by Novartis AG, H2 2016
    Anal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
    Anal Cancer - Pipeline by Oryx GmbH & Co. KG, H2 2016
    Anal Cancer - Pipeline by PDS Biotechnology Corporation, H2 2016
    Anal Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
    Anal Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Anal Cancer - Dormant Projects, H2 2016
    List of Figures
    Number of Products under Development for Anal Cancer, H2 2016
    Number of Products under Development for Anal Cancer - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Targets, H2 2016
    Number of Products by Stage and Targets, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report